Innovative Biotech Focus Vical specializes in developing DNA-based biopharmaceuticals for infectious diseases, presenting opportunities to collaborate with biotech firms seeking advanced therapeutic technologies and partnerships in genetic medicine.
Recent Strategic Mergers Following its merger with Brickell Biotech, Vical demonstrates a growth trajectory through strategic acquisitions, indicating potential for collaborations or sales involving novel therapeutic pipelines and combined research efforts.
Commercialization Licenses Vical's license agreement with Astellas Pharma for the antifungal candidate VL-2397 suggests openness to licensing deals, creating potential sales channels for complementary pharmaceutical products targeting similar markets.
Growing Market Presence With revenues between 25 and 50 million dollars and recent capital funding, Vical is positioned for expansion into new markets, providing opportunities for sales of research tools, development services, or partnering with emerging biotech initiatives.
Technological Engagement Utilizing industry-standard tech stacks like New Relic and Google Analytics, Vical is actively engaged in digital presence and data-driven development, opening avenues for sales of IT solutions, analytics services, or software tools to accelerate biotech R&D efforts.
$250M$500M
$100M$250M
$25M$50M
$1M$10M
$1B$10B
$1M$10M
$100M$250M
$500M$1B
$10M$25M
$50M$100MVical uses 6 technology products and services including jQuery, jQuery UI, New Relic, and more. Explore Vical's tech stack below.
| Vical Email Formats | Percentage |
| FLast@vical.com | 34% |
| First.Last@vical.com | 22% |
| Last@vical.com | 10% |
| FLast@vical.com | 34% |
Biotechnology ResearchUnited States201-500 Employees
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on our patented DNA delivery technologies and other therapeutic approaches. Headquartered in San Diego, CA, Vical is independently pioneering the development of paradigm-changing therapies, and is partnering with key industry leaders. Additional information on Vical is available at www.vical.com.
Company Overview
Funding & FinancialsVical has raised a total of $25M of funding over 5 rounds. Their latest funding round was raised on Nov 08, 2017 in the amount of $25M.
Vical's revenue is estimated to be in the range of $25M$50M
Funding & FinancialsVical has raised a total of $25M of funding over 5 rounds. Their latest funding round was raised on Nov 08, 2017 in the amount of $25M.
Vical's revenue is estimated to be in the range of $25M$50M
1-888-653-2347 
support@leadiq.com